Theriva Biologics (TOVX) Short-Term Debt issuances (2025 - 2026)
Theriva Biologics (TOVX) posted quarterly Short-Term Debt issuances of -$49000.0 for Q1 2026, up 12.5% year-over-year from -$43555.6 in Q1 2025, and down 4800.0% quarter-over-quarter from -$1000.0 in Q4 2025.
Theriva Biologics (TOVX) Short-Term Debt issuances (2025 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Short-Term Debt issuances for 2 consecutive years, with -$49000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-Term Debt issuances rose 12.5% year-over-year to -$49000.0; the TTM figure through Mar 2026 stood at -$63000.0 (changed N/A YoY), while the FY2025 annual figure was -$70000.0, down 4.48% from the prior year.
- Short-Term Debt issuances fell to -$49000.0 in Q1 2026 per TOVX's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at -$1000.0 in Q4 2025 and bottomed at -$56000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11,000.00 |
| Jun 30, 2026 | -11,000.00 |
| Mar 31, 2026 | -49,000.00 |
| Mar 31, 2026 | -49,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -11,000.00 |
| Mar 31, 2025 | -56,000.00 |
| Mar 31, 2025 | -56,000.00 |